Yanguang Yang
Taiyuan, 030000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Dihydroartemisinin promotes ABCG5/G8-mediated cholesterol efflux to potentiate anti-PD-1 therapy through YAP1-TEAD1 complex disruption in hepatocellular carcinoma.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: April 21, 2026
Verteporfin inhibits the cGAS-STING pathway and improves the tumor microenvironment during cisplatin treatment in hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: July 02, 2025
Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a 'hot' switch for 'cold' tumor in hepatocellular carcinoma.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: June 29, 2025
Xiaoyao powder attenuates acetaminophen-induced liver injury through modulating gut microbiota and upregulating GLYAT.
Journal: Journal of ethnopharmacology
Published: June 13, 2025
Big lessons from the little Akkermansia muciniphila in hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: November 07, 2024
Dihydroartemisinin inhibited tongue squamous cell carcinoma progression and tongue-to-lymph node metastasis through inhibiting RalB expression.
Journal: Acta histochemica
Published: October 21, 2024
RalB promotes lymph node metastasis in tongue squamous cell carcinoma.
Journal: Genes & genomics
Published: October 05, 2024
Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma.
Journal: Molecular biology reports
Published: April 24, 2024
Dihydroartemisinin modulated arachidonic acid metabolism and mitigated liver inflammation by inhibiting the activation of 5-LOX and COX-2.
Journal: Heliyon
Published: March 19, 2024
Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma.
Journal: Biochemical pharmacology
Published: February 11, 2024
Lycium barbarum L. Balanced intestinal flora with YAP1/FXR activation in drug-induced liver injury.
Journal: International immunopharmacology
Published: January 02, 2024
Last Updated: 09/26/2026